Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history of HZ. Participants (stratified by age: 50–59, 60...

Full description

Bibliographic Details
Main Authors: Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, Himal Lal
Format: Article
Language:English
Published: Taylor & Francis Group 2017-05-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
immunogenicity
safety
varicella-zoster virus
zoster vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2016.1265715

Internet

http://dx.doi.org/10.1080/21645515.2016.1265715

Similar Items